Wednesday, March 18, 2009

TGen’s Dr. Von Hoff Wins Award for Cancer Research

PHOENIX, Ariz. - March 17, 2009 - Dr. Daniel Von Hoff, Physician-In-Chief of the Translational Genomics Research Institute (TGen), has won an award recognizing his achievements in cancer research.

Dr. Von Hoff, who also is Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare, will be recognized in the category of Health Care Research in a special report this month in Arizona Business Magazine. Dr. Von Hoff was honored March 4 at the magazine's 2009 Health Care Leadership Awards at the Ritz Carlton Phoenix.

This is the second major award in recent months for Dr. Von Hoff, a world-renowned cancer scientist and one of the leading experts in pancreatic cancer. In November, Dr. Von Hoff was named Arizona's Community Service Leader of the Year at the 2008 Governor's Celebration of Innovation, presented annually for contributions to Arizona’s technology industry through relentless community involvement, leadership, visibility and excellence in economic development activity.

For more than 30 years, Dr. Von Hoff has dedicated his time and experience to the study of cancer and treatment methods. Arizona Business Magazine cited his:

International leadership in bringing to patients new anti-cancer agents – many of which have been shown to increase patient survival.

Study of pancreatic and other forms of cancer.

Dedication to teaching.

Entrepreneurial research efforts, which have led to 12 patents.
Through the three-year-old partnership between TGen and Scottsdale Healthcare, Dr. Von Hoff leads a nearly 40-member staff in the research and treatment of cancer. TCRS at Scottsdale Healthcare is conducting 35 ongoing studies, involving the treatment of many patients with advanced cancer. The alliance works to identify new anti-cancer agents, and strives to bring diagnostic and treatment options to patients as fast as possible.

Dr. Von Hoff earned his medical degree from Columbia College of Physicians and Surgeons. He held an internship and residency at the University of California, San Francisco; conducted four years of cancer research at the National Cancer Institute; and worked as a faculty member at the University of Texas.

In Arizona, he has worked as Director of the Arizona Cancer Center in Tucson and as a Clinical Professor at the University of Arizona College of Medicine.

Dr. Von Hoff holds a presidential appointment to the National Cancer Advisory Board, is widely published and has been a keynote speaker at numerous national and international medical and scientific conferences.

# # #

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.


Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , , ,

Monday, March 09, 2009

Applied Biosystems and Translational Genomics Research Institute Accelerate use of Genomics Research for Medical Applications

Enhanced understanding of genetic basis of disease to hasten advent of personalized medicine

Phoenix, AZ – March 9, 2009 – Applied Biosystems, a division of Life Technologies Corporation (NASDAQ: LIFE), and the Translational Genomics Research Institute, today announced a strategic alliance designed to accelerate research into complex diseases and medical conditions. As part of this alliance, a team of scientists from TGen and Applied Biosystems will employ the SOLiD™ 3 System, Applied Biosystems’ next-generation genomic analysis platform, to sequence DNA from thousands of patients with a variety of diseases. The goal of this research is to translate scientific discoveries at the genetic level into knowledge about the underlying causes of disease that may ultimately be used to create cutting-edge tools for use in clinical diagnosis.

The alliance enables TGen researchers to apply best-of-breed sequencing technology across a broad spectrum of research efforts that focus on developing a more personalized approach to medicine. This approach, which is known as personalized medicine, represents a potential clinical shift from treatment of disease based on symptoms, to therapy that is specific to an individual’s unique genetic make up. Among the goals of this project is to advance the promise of personalized medicine by reducing the cost of genome sequencing to make it a routine diagnostic tool in medical care.

“This strategic alliance will accelerate genomic discoveries by integrating relevant scientific findings into the clinical setting,” said Mark Stevenson, President and Chief Operating Officer of Life Technologies. “The SOLiD System will help this team of scientists and other researchers and clinicians interpret how genetic variation can improve the ability to create more effective therapeutic solutions, bringing personalized medicine one step closer to mainstream application.”

The scientists involved in this alliance will utilize a total of five SOLiD 3 Systems to build a sequencing pipeline in connection with patient-centric, medically-directed resequencing on a cross section of patient samples. The results are expected to positively impact individuals with cancer, autoimmune and neurological disorders. The alliance will also involve the co-development of a bioinformatics analysis and visualization pipeline for the SOLiD platform. This will result in software tools designed to ease the analytical challenges associated with analyzing the vast amounts of data generated by human disease and cancer genomics applications of next generation sequencing.

Dr. Jeffrey Trent, President and Scientific Director of TGen, and other renowned principal investigators will partner with Applied Biosystems scientists to perform six different projects focused on comprehensive characterization of genetic and molecular changes occurring within clinical cohorts for each disease. The scientists at TGen chose the SOLiD technology for this project, due to its inherent scalability, unparalleled throughput and unmatched data accuracy. These attributes make the SOLiD System uniquely suited for translational research of complex diseases by enabling the detection of single nucleotide polymorphisms and other structural variation across the genome in large numbers of samples.

“Consistent with TGen’s mission of developing the next generation of diagnostics and therapeutics, the alliance with Applied Biosystems forges ties with a key industry partner whose technologies align seamlessly with our research objectives and should produce accelerated progress in our efforts to better understand the genetic underpinnings of many diseases, with a particular emphasis on cancer,” said Dr. Trent.

Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. The technologies it markets include a robust line of DNA sequencing systems and chemistries to meet the increasing demands of the scientific community for higher throughput, more sophisticated DNA sequencing solutions. Applied Biosystems, together, with Invitrogen – a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics – is part of Life Technologies Corporation, which markets the life science industry’s most comprehensive portfolio of solutions for molecular and cell biology. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.

TGen is a growing leader in integrating medically directed technologies and applications into clinical practice, the results of which provide real solutions for patients. Through its recent alliance with the Van Andel Research Institute in Grand Rapids, Michigan, TGen and VARI now have a national outreach to patient populations across multiple diseases. That alliance combines the groundbreaking basic research expertise of VARI with the cutting-edge translational genomics and analysis capabilities of TGen.

For more information, please visit: www.appliedbiosystems.com, www.invitrogen.com and www.tgen.org

About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org

Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , , , , ,

Friday, March 06, 2009

Safeway gives $685,000 to TGen for Breast Cancer Research

Arizona grocery chain increases contribution to TGen by 37 percent over 2008

PHOENIX, Ariz. - March 4, 2009 - Despite a down economy, Safeway Inc. presented a $685,236 check this week for breast cancer research at the Translational Genomics Research Institute (TGen). Dan Valenzuela, President of Safeway's Phoenix Division, which includes 116 stores throughout Arizona, thanked the grocery chain's customers and employees for stepping up for scientific research.

Safeway presents a check for $685,236 to TGen for breast cancer research
From left are: Dr. Heather Cunliffe, a TGen breast cancer researcher; Dan Valenzuela, President of Safeway Inc.'s 116 Arizona stores; Cathy Kloos, Safeway's Phoenix Division Public Affairs Director; Erin Massey, TGen Foundation Director of Development; and Michael Bassoff, President of the TGen Foundation.

"We're very proud to donate to such an organization as TGen. I think everybody recognizes that, with the economy the way it is, it gets tougher to ask people for donations," Valenzuela told about 50 TGen employees gathered Tuesday for the announcement. "Because of your research, and the things that you do, we're honored to present you with a check."

Safeway's donation represents a 37 percent increase from the $500,000 the company gave TGen last year. The contributions both years were based on month-long campaigns at Arizona's Safeway stores in October 2007 and October 2008.

"You can't give enough credit to our customers and employees," Valenzuela said, adding that a major reason Safeway chose to support Phoenix-based TGen was that the research dollars would stay in Arizona.

"The benefit (of TGen's research) is far-reaching. The big thing is, where do the funds go? It (TGen) is local," Valenzuela said.

Dr. Jeffrey Trent, TGen's President and Scientific Director, said the significant and timely contribution by Safeway is an example of the generosity repeatedly shown by local businesses and the people of Arizona.

"This donation will be put to immediate use to help develop treatments and, eventually, find a cure for breast cancer, a major priority for us at TGen and a goal that would benefit everyone," Dr. Trent said.

Michael Bassoff, President of the TGen Foundation, the fundraising arm of the non-profit biomedical research institute, described Safeway's contribution as a special tribute to TGen researchers as they work to conquer cancer and other debilitating diseases.

"Contributors are looking hard at their charitable opportunities and are looking for the organizations that are run efficiently and produce results," Bassoff said. "But today's donation by Safeway is a tribute to you, the work you do in the laboratories, and the many Arizonans who came forward to support TGen," Bassoff told the assembled TGen employees.

Dr. Heather Cunliffe, a TGen breast cancer researcher, said Safeway's donation would help accelerate work towards new treatments for breast cancer patients.

Bassoff also credited the "extra gumption" and hard work of Safeway employees who were willing to ask customers if they would contribute to breast cancer research.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.


Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , ,

Tuesday, February 17, 2009

High Tea Raises High Hopes For Tgen Ovarian Cancer Research

High tea raises high hopes for TGen ovarian cancer research

PHOENIX, Ariz. - Feb. 16, 2009 - The Anne Rita Monahan Foundation will host Tea for Teal, a high English afternoon tea, to fund ovarian cancer research by the Translational Genomics Research Institute (TGen).

The Tea for Teal is at 2 p.m. Saturday, Feb. 28, at the Sheraton Downtown Phoenix, 340 N. Third St., part of the Anne Rita Monahan Foundation's efforts to raise $100,000 for ovarian cancer research.

Just as pink is the color representing the fight against breast cancer, teal is the color that represents the fight against ovarian cancer.

Funds will be used to research early-stage, drug-resistant ovarian cancer. TGen scientists are searching for a reliable early-screening tool and better drug treatments.

The Anne Rita Monahan Foundation was established by Anne Rita Monahan of Phoenix, a heroic ovarian cancer fighter, in an effort to warn other women about the disease, which she continues to fight daily.

Because the disease is often difficult to detect in its early stages, the Anne Rita Monahan Foundation is focused on education about the early signs and symptoms of ovarian cancer. The Foundation also funds research into the discovery of an effective, reliable screening tool that would help detect this type of cancer as soon as possible, giving women the best opportunities for remission.

The Anne Rita Monahan (ARM) Foundation's effort to eradicate ovarian cancer includes outreach and educational programs for the public and for the medical community. The Foundation urges women to "ARM Yourself Against Ovarian Cancer."

Anne Rita Monahan Foundation Tea for Teal

For more information or to register:

www.anneritamonahan.org or 602-264-5539.

Participation fees:

Individual tickets are $60; a table of 10 is $500.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to the performance of groundbreaking research with life changing results. Research at TGen is focused on developing earlier diagnostics and smarter treatments for diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated to the diagnosis and treatment of disease in a manner tailored to individual patients.


Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: , , , , , , , , , ,

Thursday, October 30, 2008

TGEN Officials Dr. Michael Berens and MaryAnn Guerra Appointed to Arizona Technology Council board of directors

TGEN Officials Dr. Michael Berens and MaryAnn Guerra Appointed to Arizona Technology Council’s board of directors

Biotech News
AZhttp, Inc.

Two top TGen officials appointed to new positions on the Arizona Technology Council’s board of directors


Dr. Michael Berens and MaryAnn Guerra - two top officials of the Translational Genomics Research Institute (TGen) - have been appointed to new positions on the board of directors of the Arizona Technology Council.

Dr. Berens, Director of TGen's Cancer and Cell Biology Division, was named Chairman Emeritus on the ATC board, one of four new executive officers named to two-year terms. Dr. Berens, who has served six years on the board - the past two as Chairman of the nearly 500-member organization - also was one of five Director's Emeritus named to serve indefinite terms on the board.

"It is an honor to be named by my peers on the board as one of the organization's leaders. My goal is to strengthen the Arizona Technology Council's efforts to grow the state’s knowledge-based industries by helping to promote key national and international business partnerships," Dr. Berens said.
Guerra, TGen's Chief Business Officer and President of TGen Accelerators LLC, was one of 10 new directors appointed to three-year terms on the 33-member board, following its Oct. 23 meeting.

"Being named to the board is an honor, and presents an exciting opportunity to help the Arizona Technology Council work to diversify the state's economic base with high-paying jobs in the fast-growing fields of medicine, technology and innovation," Guerra said.
The board represents the interests of Arizona's technology industries and advises ATC in its expressed goals of promoting research, education and access to a highly skilled workforce.

Three other newly appointed board executive officers are: Chairman Steve Phillips, CIO of Avnet; Secretary Ray Harris Esq., director of Fennemore Craig; and Treasurer Kevin McHolland, CPA and partner of Ernst & Young.
"The Arizona Technology Council has been the principal point of connection for technology companies," Phillips said. "As the new chairman, I will oversee an agenda that continues to build valuable programs and services for all members and supports technology innovation and growth."

Nine other newly appointed directors are: David Beauchamp, partner, Bryan Cave; Thomas Campbell, partner, Lewis and Roca; Kathleen A. Collins, Mesa functional chief engineer, Boeing; John Cummerford, shareholder, Intellectual Property & Technology, Technology, Media & Telecommunications, Greenburg Traurig; Joe Drazek, partner, Quarles and Brady; Carl Lytikainen, senior vice president of Technical Services, Lumension Security; Jane Poynter, president, Paragon Space Development Corporation; Dr. R. F. "Rick" Shangraw, vice president for Research and Economic Affairs, Arizona State University; and Judith K. Weiss, partner, Perkins Coie Brown & Bain.

Four other Director's Emeritus are: Joanne Carthey Bradley, COO, Namescape Corporation; Charles Jirauch, partner, Quarles & Brady LLP; Quinn Williams, shareholder, Greenberg Traurig LLP; and Mark Schonau, CFO, Insysrx.

Steven G. Zylstra, President and Chief Executive Officer of ATC, remains as an executive officer.

# # #

About the Arizona Technology Council

The Arizona Technology Council is a private, not-for-profit trade association founded to connect, represent and support the state's expanding technology industry. To promote economic growth and professional development in Arizona's technology sector, the Council provides members networking opportunities, business support and access to educational forums. The Council strives to distinguish Arizona as a leader in the technology community and offer resources that are exclusive to its members. www.aztechcouncil.org.

About TGen

The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. www.tgen.org.

About TGen Accelerators LLC
A firm designed to quickly translate TGen's genetic research discoveries into medical treatments and services.



Biotechnology Marketing

Labels: ,

Wednesday, October 15, 2008

Daniel Von Hoff finalist for William F. McWhortor Community Service Leader of the Year award

TGen’s Dr. Daniel Von Hoff is a finalist for prestigious Arizona technology community service award


Dr. Daniel Von Hoff PHOENIX, Ariz. - Oct. 15, 2008 -- Dr. Daniel Von Hoff, TGen's Physician-in-Chief, is one of three nominees for the 2008 William F. McWhortor Community Service Leader of the Year award.

Biotech News

The McWhortor award is presented annually to an individual or organization from industry, government or academia that contributes to Arizona's technology industry through relentless community involvement, leadership, visibility and excellence in economic development activity.

The winner will be announced during the Governor's Celebration of Innovation from 5-7 p.m. Nov. 13 at the Dodge Theatre, 400 W. Washington St., Phoenix. The awards are organized through the Governor's Office, the Arizona Department of Commerce and the Arizona Technology Council.

Dr. Von Hoff also is Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare, Clinical Professor of Medicine at the University of Arizona, and a member of the Mayo Clinic's Comprehensive Cancer Center.

In addition to being an accomplished and recognized cancer scientist, Dr. Von Hoff has been tireless in what he has brought to the Arizona community. He is a founder of TGen, a founder of the non-profit International Genomics Consortium based in Phoenix, and has helped bring countless other jobs to this community. His commitment was instrumental in helping establish the Scottsdale Clinical Research Institute, a hospital-based research institute that serves as a bridge between cure and care. It is one of the finest programs in the nation in its ability to help patients with advanced cancer. It is emblematic of the translation of discoveries in genomic science to specific treatments for individual patients.

Dr. Von Hoff is committed to the professional advancement of younger colleagues, recruiting young investigators and incorporating teaching into every staff meeting. With his encouragement and guidance, younger scientists develop new research and present findings.

His warmth and humor sustain his staff in one of the most challenging fields of medicine, and his colleagues and staff refer to him as the "heart and soul" of the cancer research program.

Dr. Von Hoff earned his medical degree at Columbia College of Physicians and Surgeons in 1973. Following an internship and residency at the University of California, San Francisco, he spent four years at the prestigious National Cancer Institute in Bethesda, Md.

After experience at the forefront of cancer research at NCI, he joined the faculty of the University of Texas in San Antonio, where during the next 20 years he expanded the knowledge of cancer biology and tumor growth factors.

Dr. Von Hoff moved to Arizona in 1999, serving as Director of the Arizona Cancer Center in Tucson, and as Professor at the University of Arizona College of Medicine in Tucson, before joining TGen.

In addition to his other duties, Dr. Von Hoff is serving a six-year presidential appointment (June 2004-March 2010) on the National Institutes of Health's National Cancer Advisory Board. He also is past president of the American Association for Cancer Research, which with more than 28,000 members is the world's largest cancer research organization. He has published more than 540 scientific papers, more than 130 book chapters, and nearly 950 scientific abstracts. He is the holder of a dozen patents for new anti-cancer agents and medical devices.

For more than 35 years, Dr. Von Hoff has been devoted to advancing the understanding and treatment of cancer. His programs have two main goals:

-- Applying new knowledge to identify the best new targeted anti-cancer agents to treat individual cancer patients.

-- Curing pancreatic cancer.

The William F. McWhortor Community Service Leader of the Year award is named in honor of the late co-founder of the Arizona Innovation Network and its successor professional groups in Arizona, including the Arizona Technology Council, which have supported creative technological thinking. McWhortor, a Fountain Hills resident who died in 1997, patented a pattern recognition device in 1989 to help stop counterfeit checks.

Past winners of the McWhortor award include:

-- Ira A. Fulton, chairman and chief executive officer of Tempe-based Fulton Homes Inc.

-- Former Arizona State University President Lattie Coor.

-- Richard Mallery, partner and founding director of the Phoenix law firm Snell & Wilmer, for his successful efforts to bring the Translational Genomics Research Institute to Arizona.

###

AZhttp, Inc.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.

Biotechnology Marketing

Labels: , ,

Tuesday, April 22, 2008

Two New Therapies Show Promise for Cancer Patients

Two New Therapies Show Promise for Cancer Patients

Clinical trial data and cutting-edge testing give key insights in the fight
against basal cell carcinoma and pancreatic cancer.

San Diego and Phoenix-April 15, 2008-Clinical researchers at Scottsdale
Healthcare and TGen today announced the results of two clinical trials that
show promise for patients battling cancer.

The Phase I clinical trial findings, presented at the this weeks Annual
Meeting of the American Association for Cancer Research by Daniel Von Hoff,
MD, FACG, focused on basal cell carcinoma (BCC) and pancreatic cancer. The
Arizona trials were conducted at TGen's Clinical Research Service (TCRS) at
Scottsdale Healthcare, a strategic alliance between TGen and Scottsdale
Healthcare's Clinical Research Institute.

Basal Cell Carcinoma In the first trial, a novel molecule, GDC-0449, shrinks
tumors in basal cell carcinoma (BCC) while having limited side effects,
including a loss of sense of taste, and a small amount of hair loss and
weight loss, suggesting a viable new treatment option. GDC-0449 works by
blocking a pathway - a series of chemical reactions within a cell- known as
Hedgehog, containing two genes (PTCH and SMO) that lead to a known
tumor-promoting gene called GLI1. Alterations in any of these genes have
been shown to lead to basal cell carcinoma and other diseases. GDC-0449 is a
chemical synthetic designed to replicate the properties of cyclopamine, a
chemical found in nature.

"Basal cell carcinoma affects about one million people a year and a
proportion of these patients have disease that is not curable with surgery.
We currently do not have any treatments that can effectively slow tumor
growth in these advanced patients. This finding has potential importance in
this population," said Daniel D. Von Hoff, M.D., Physician in Chief at the
Translational Genomics Research Institute (TGen) and Chief Medical Officer
for the Scottsdale Clinical Research Institute at Scottsdale Healthcare.

Typically diagnosed with a simple biopsy, the risk of BCC increases for
those individuals with a family history, or prolonged exposure to
ultraviolet (or UV) rays from the sun. While BCC has an extremely low rate
of metastasis, it can lead to scarring and disfigurement if left untreated.

The trial results showed durable clinical benefit -defined as tumor
shrinkage visible on X-ray or other physical exam or improvement in symptoms
without tumor growth- was observed in eight out of the nine patients
evaluated.

The first patient treated in the trial has shown clinical improvement for
approximately 450 days and is ongoing, Von Hoff says, with almost no side
effects beyond minimal hair loss.

"He came to us short of breath and in pain, but he has had a very dramatic
response with this drug," Von Hoff said.

Further evaluations of the study participants measured the presence of GLI1
in skin cells sampled from the participants. Among all patients tested to
date, there was reduction in this marker, indicating that the drug was
affecting the hedgehog pathway.

The trial, sponsored by Genentech, also included clinical sites at the
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
Baltimore, Maryland and Karmanos Cancer Institute, Detroit, Michigan.

Pancreatic Cancer In the second trial, Von Hoff and colleagues showed that a
novel combination of two drugs (nanoparticle albumin-bound paclitaxel, or
"nab-pacilitaxel" and gemcitabine) showed a significant clinical benefit in
more than 80 percent of pancreatic cancer patients. "Unfortunately, most
patients with pancreatic cancer have a very poor survival, and until now,
the only option has been gemcitabine alone or in combination with
erlotinib," said Von Hoff.

The researchers utilized the Target NowT tumor profiling analysis, a
cutting-edge oncology testing service performed by Caris Dx and Caris MPI,
to better understand the characteristics expressed in patient's tumors. In
this ongoing research program, Von Hoff and colleagues found the SPARC
(Secreted Protein Acidic and Rich in Cysteine) protein to be commonly found
in pancreatic cancer specimens. The SPARC protein is being investigated by
Abraxis BioScience in this trial as a potential target for nab-paclitaxel. A
test for SPARC, developed at Abraxis and Caris MPI and applied by Caris MPI
under contract with Abraxis, was utilized to analyze SPARC in the pancreatic
cancer patients in the trial.

The finding of SPARC protein in pancreatic cancer patients, also described
by other investigators, was the basis for this phase I clinical trial that
Von Hoff presented at AACR.

"Chemotherapy often means combining more than one drug, and we do not want
to just take the next thing off the shelf. We want to know as much about a
tumor as possible going in," Von Hoff said.

Researchers reported on the first 20 patients of what will eventually be a
42-patient trial.

"This was a phase I trial, and phase I trials are usually designed to test
safety, hoping it will also determine efficacy. The fact that we saw this
kind of activity in a phase I trial is dramatic," Von Hoff said.

"The rationale behind the combination of Gemcitabine plus Abraxane was based
on careful science and was designed and executed by some of the leading
experts in pancreas cancer in the world. While the data is preliminary and
longer follow-up will be important, the biochemical and radiographic
responses look very encouraging", says Dr. Laheru of Johns Hopkins Kimmel
Cancer Center.

The trial, sponsored by Abraxis BioScience, also included clinical sites at
South Texas Oncology and Hematology, P.A., San Antonio, Texas, University of
Alabama at Birmingham, Birmingham, Alabama, and the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins University, Baltimore,
Maryland.

About Abraxis BioScience Abraxis BioScience is a fully integrated global
biotechnology company dedicated to the discovery, development and delivery
of next-generation therapeutics and core technologies that offer patients
safer and more effective treatments for cancer and other critical illnesses.
The company's portfolio includes the world's first and only protein-bound
nanoparticle chemotherapeutic compound (ABRAXANE), which is based on the
company's proprietary tumor targeting technology known as the nabT platform.
The first FDA approved product to use this nabT platform, ABRAXANE, was
launched in 2005 for the treatment of metastatic breast cancer. Abraxis
trades on the NASDAQ Global Market under the symbol ABBI. For more
information about the company and its products, please visit
http://www.abraxisbio.com/.

About Caris Caris Dx provides world-class surgical pathology services to
physicians who treat patients in an ambulatory setting. The company provides
academic-caliber medical consults through its industry-leading team of
subspecialty fellowship and expert-trained pathologists in gastrointestinal
and liver pathology, hematopathology and dermatopathology. Caris Diagnostics
provides the highest levels of service to its customers and their patients
through its state-of-the-art laboratories; proprietary, advanced clinical
and technology solutions; and rigorous quality assurance programs.

Caris MPI is a leading molecular diagnostic company that provides
world-class genomic and proteomic analysis in the field of oncology and
other complex diseases. Caris MPI translates the latest discoveries made in
the research lab to patient care. Furthermore, the Tissue Banking and
Analysis Center (TBAC) at Caris MPI assists pharmaceutical companies and
researchers in their clinical trials for tissue procurement, preservation of
key analytes for cutting edge genomic and proteomic analysis and reporting
by CMPI.

About Scottsdale Healthcare Scottsdale Healthcare's vision is Setting the
Standard for Excellence in Personalized Healthcare. Established in 1962,
Scottsdale Healthcare is the not-for-profit parent organization of the
Scottsdale Healthcare Osborn, Scottsdale Healthcare Shea and Scottsdale
Healthcare Thompson Peak hospitals, Virginia G. Piper Cancer Center,
Scottsdale Clinical Research Institute, Scottsdale Healthcare Home Health
Services and Scottsdale Healthcare Community Health Services. Based in
Scottsdale, Arizona, Scottsdale Healthcare is governed by a volunteer board
of directors composed of leading local citizens. http://www.shc.org/

About TGen The Translational Genomics Research Institute (TGen) is a
non-profit 501(c)(3) organization dedicated to conducting groundbreaking
research with life changing results. Research at TGen is focused on helping
patients with diseases such as cancer, neurological disorders and diabetes.
TGen is on the cutting edge of translational research where investigators
are able to unravel the genetic components of common and complex diseases.
Working with collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency and
effectiveness of the translational process. TGen's vision is of a world
where an understanding of genomic variation can be rapidly translated in a
manner tailored to individual patients. For more information about TGen,
please visit http://www.blogger.com/www.tgen.org.

Biotech News
AZhttp, Inc.
Biotechnology Marketing

Labels: , , , ,